pegfilgrastim-bmez Ziextenzo
Selected indexed studies
- Filgrastim. (, 2006) [PMID:30000432]
- Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. (J Med Econ, 2020) [PMID:32323582]
- Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation. (Ann Hematol, 2023) [PMID:37079070]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Filgrastim. (2006) pubmed
- Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. (2020) pubmed
- Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation. (2023) pubmed